Sequenom, Inc.(NASDAQ:SQNM) shares climbed 7.32% to $2.64. Sequenom, Inc. (Sequenom) is a molecular diagnostic testing and genetics analysis company committed to providing molecular diagnostic testing services, and research use only products, services, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock, and other areas of research.
Free Urgent Insider Catalyst Report For SQNM Available Here
Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) shares declined 2.40% to $3.66. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections.
Free Urgent Insider Catalyst Report For ACHN Available Here
Athersys, Inc.(NASDAQ:ATHX) shares gained 3.32% to $4.05. Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials.
Free Urgent Insider Catalyst Report For ATHX Available Here
Dendreon Corporation(NASDAQ:DNDN) shares increased 2.11% to $2.91. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company’s product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company’s first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Free Urgent Insider Catalyst Report For DNDN Available Here